Wednesday, July 19, 2023
LianBio's partner, Nanobiotix, has entered into a licence agreement with Janssen Pharmaceutica for the investigational radioenhancer NBTXR3.
Under the agreement, Nanobiotix will grant Janssen a worldwide licence for the co-development and commercialisation of NBTXR3, with the exception of territories previously licenced to LianBio.
This partnership with Janssen will provide Nanobiotix with additional expertise and financial resources to further develop NBTXR3 in areas of high unmet medical need.
LianBio had previously obtained rights from Nanobiotix in May 2021 for the development and commercialisation of NBTXR3 in several Asian territories, including Mainland China, Hong Kong, Macau, Taiwan, Thailand, South Korea, and Singapore.
NBTXR3 is a potentially groundbreaking oncology product made up of functionalized hafnium oxide nanoparticles. It is administered through a one-time intratumoral injection and activated by radiotherapy. The product's mechanism of action is designed to cause significant tumour cell death in the injected tumour when activated by radiotherapy.
This process subsequently triggers an adaptive immune response and long-term anti-cancer memory. The unique physical mechanism of action of NBTXR3 makes it potentially applicable to various solid tumour indications and therapeutic combinations, including immune checkpoint inhibitors.
